-
FDA approves Persimmon Squibb's PD-1 mono-anti-Opdivo and CTLA-4 mono-anti-Yervoy combination, first-line treatment of non-small cell lung cancer
Time of Update: 2020-05-29
Bristol Myers Squibb announced that the FDA has approved a combination of its PD-1 mono-antiOpdivo (nivolumab) and CTLA-4 monoantigen Yervoy (ipilimumab) to treat patients with metastatic non-smal
-
Coating knowledge: a total of 259 households in China have paid coating consumption tax
Time of Update: 2020-04-03
Core tip: the data shows that there are 259 taxpayers of paint consumption tax in China at present, with few taxpayers involved and small tax share Since February 1 this year, China has imposed a cons
-
Increase in domestic orders, titanium dioxide prices firm and stable
Time of Update: 2020-03-16
market analysis in Mid March, the price of titanium dioxide gradually strengthened, the exchange market real single transaction price slightly floated, mainly due to high raw material sitority cost
-
JAMA network open: why do antibiotics affect childhood obesity
Time of Update: 2020-01-24
January 24, 2020 / bioin / - children who receive multiple antibiotic prescriptions early in life may be prone to obesity, according to new research In the first study, the researchers found that four
-
Cs1001 combined with chemotherapy for esophageal squamous cell carcinoma
Time of Update: 2020-01-08
Cornerstone Pharmaceutical (Suzhou) Co., Ltd According to the data of GLOBOCAN in 2018, 307 thousand cases of new cases of esophageal cancer occur in China every year, and 283 thousand cases of deaths
-
5% off, only 4 yuan to win over 90% of the national medical representatives
Time of Update: 2019-12-03
Last night in my dream, my heart told me: all efforts, thrift, and collecting wool are for the last good! In the happy trio, Gina and Lang Lang enjoy the Erhai Lake scene in Yunnan Province, admiring
-
Famous pharmaceutical companies shut down a production line due to anti drug restrictions and environmental factors
Time of Update: 2019-11-20
Yan'an Bikang announced that due to factors such as anti drug restriction and environmental protection, a product line of its subsidiary was shut down, which, to some extent, is a small epitome of the
-
Good news for nearsighted children! FDA approved the first contact lens to delay the development of myopia in children
Time of Update: 2019-11-17
On November 16, the FDA announced the approval of the first contact lens for delaying the development of myopia in children aged 8-12 The contact lens, called misight, is a disposable soft contact len
-
Jingfeng pharmaceutical lost 140 million in the first three quarters, down 200% year on year
Time of Update: 2019-10-30
On October 28, Jingfeng pharmaceutical released the third quarter quarterly report, and the overall operating revenue declined seriously, which was not optimistic Since 2019, the operating revenue has
-
Blyngju G John: growth and investment in 2018
Time of Update: 2019-04-18
Highlights 1 Research pipeline filling in the fields of tumor, fibrotic disease, immune and metabolic disease 2 The business growth of all businesses has exceeded the market average 3 The animal healt
-
State Food and Drug Administration: Niuhuang Jiedu tablet is forbidden for infants
Time of Update: 2019-03-11
Recently, the State Drug Administration issued a notice, according to the evaluation results of adverse drug reactions, in order to further ensure the safety of drug use by the public, the State Drug
-
Erkang's net profit dropped 56.65% year on year, mainly due to these three points
Time of Update: 2019-02-28
On February 27, Erkang Pharmaceutical (300267) released the performance express report From January to December 2018, the company achieved an operating revenue of 2.380 billion yuan, a year-on-year de
-
"4 + 7" with quantity purchase, the first detailed rules document is coming
Time of Update: 2019-01-11
[China Pharmaceutical network industry trends] recently, Dalian City issued the "implementation of the work plan for centralized procurement and use of drugs organized by the state (Draft for comments
-
[performance forecast] Zhifei biology: net profit in 2018 increased by 223% to 252
Time of Update: 2019-01-04
Zhifei Biology (300122) released the performance forecast on the evening of January 3 It is estimated that the net profit in 2018 will be 1.396 billion yuan to 1.522 billion yuan, a year-on-year incre
-
Nature catalysis: the research group of Professor Shi Zhuangzhi of Nanjing University has made progress in the regulation and control of boronization by copper catalysis
Time of Update: 2018-11-25
Borate esters are widely used in materials, drugs and chemical synthesis In recent years, the preparation of borate esters by transition metal catalyzed coupling has attracted people's attention, whic
